The expansion of Batten Disease treatment options is crucial to our community’s future. We are excited to share this announcement from REGENXBIO who plans to submit an IND for a new gene therapy for CLN2 in 2019. Because of news like this, we continue to be hopeful about progress for patients and families. You can read the full press release here.
You are here: / / REGENXBIO Announces Pipeline Expansion with RGX-181 Gene Therapy for CLN2 Form of Batten Disease